JCJustine Clarenne

Justine Clarenne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Justine Clarenne has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prédiction de l’impact clinique, économique et organisationnel des interventions pharmaceutiques par apport des méthodes d’intelligence artificielle

    by Justine Clarenne

    L’évaluation de la pertinence des interventions pharmaceutiques (IP) à travers leur impact clinique, économique et organisationnel constitue un enjeu majeur pour la valorisation des activités de pharmacie clinique.L’objectif de ce travail était de développer une méthode de prédiction de l’impact des interventions pharmaceutiques. Dans un premier temps, une analyse des interventions pharmaceutiques documentées sur l’observatoire national Act-IP© entre 2017 et 2021 nous a permis de mettre en évidence que les méthodes statistiques classiques n’étaient plus adaptées aux données massives. De plus, les données textuelles des interventions n’étaient pas exploitées. Nous avons également proposé une nouvelle technique de visualisation des données.Dans un second temps, un travail préliminaire de labellisation des données textuelles a été réalisé. Puis, nous avons proposé deux méthodes de prédiction de l’impact des IP : une méthode de forêt aléatoire et un modèle linéaire généralisé. Ces deux méthodes ont été développées pour chacun des trois impacts et à partir de deux jeux de données : un jeu comportant uniquement des données structurées et un jeu comportant à la fois des données structurées et textuelles. La méthode la plus performante était celle de la forêt aléatoire appliquée sur les données structurées et textuelles, ce qui a montré l’intérêt de l’exploitation des données textuelles.La perspective de ce travail est de construire par la suite des méthodes prédictives multi-classes afin d’obtenir une prédiction d’impact plus précise et de mettre cela à disposition des pharmaciens pour les guider dans l’évaluation de l’impact des interventions pharmaceutiques.

  • Open Access

    Référentiel de compétences « Méthodologie de Pharmacie Clinique » à destination des enseignants

    by Jean-François Huon, Céline Mongaret, Laurence Spiesser-Robelet, Julien Gravoulet, Justine Clarenne, Benoît Allenet, Nicolas Simon, Mathilde Strumia, Sébastien Chanoine, Marie-Camille Chaumais

  • Predictive factors for delayed high-dose methotrexate elimination: A practical issue for diffuse large B-cell lymphoma patients

    by Margot Vattaire-Hervé, Antoine Le Bozec, Justine Clarenne, Guillaume Cohet, Violaine Lepage, Chloé Gossery, Elise Michelet-Huot, Anne Quinquenel, Isabelle Madelaine, Eric Durot, et al.

    Purpose: The high-dose methotrexate (HD-MTX) regimen (>1 g/m 2 ) is the standard of care for preventing and managing central nervous system (CNS) invasion in diffuse large B-cell lymphoma (DLBCL). Delayed elimination of HD-MTX can lead to severe toxicity. Albumin is a suggested biological marker to predict delayed elimination. This study aims to evaluate whether serum albumin can be used as a predictive factor. Methods: This retrospective bicentric study includes DLBCL patients, receiving HD-MTX from 06.30.2016 to 12.31.2023 using CHIMI0v5.9. Data collected included demographic, biological, clinical and therapeutic. Eligible patients were over 18 years, with DLBCL diagnosis, available serum albumin before HD-MTX, with therapeutic drug monitoring of plasma methotrexate available. Univariate and multivariate analysis compared patients with and without delayed elimination. Results: A total of 68 patients were included, with 15 suffering delayed elimination. Univariate analysis showed that male and Body Surface Area ≥ 2 m² (BSA) patients were more likely to have delayed clearance (respectively p = 0.01; p = 0.05). The association with male sex was confirmed in multivariate analysis (p = 0.01). Most cases of hypoalbuminemia were classified as grade 1 or 2. Patients with hypoalbuminemia received lower doses of MTX. Serum albumin level was not significantly associated with delayed elimination (p = 0.8). Conclusions: Overall, mainly biometric factors are associated with delayed elimination, highlighting the problem of prescribing habits based on body surface area. Albuminemia's role remains debated, and this study does not provide a conclusion, as patients with hypoalbuminemia received lower HD-MTX doses. Studies should account factors related to inflammation, nutrition and specific biomarkers (prealbumin).


  • Open Access

    A machine learning-based clinical predictive tool to identify patients at high risk of medication errors

    by Ammar Abdo, Lyse Gallay, Thibault Vallecillo, Justine Clarenne, Pauline Quillet, Vincent Vuiblet, Rudy Merieux

    A medication error is an inadvertent failure in the drug therapy process that can cause serious harm to patients by increasing morbidity and mortality and are associated with significant economic costs to the healthcare system. Medication reconciliation is the most cost-effective intervention and can result in a 66% reduction in medication errors. To improve patient safety, we developed a machine learning-based tool that prioritizes patients at risk of medication errors upon admission to the hospital to ensure that they undergo medication reconciliation by clinical pharmacists. The data were collected from the electronic health records of patients admitted to Reims University Hospital who underwent medication reconciliation between 2017 and 2023. The data from 7200 patients were used to train four machine learning-based models based on 52 variables in the development dataset. These models were used to prioritize admitted patients according to their likelihood of being exposed to a medication error. Our models, particularly the voting classifier model, demonstrated good performance (a recall of 0.75, precision of 0.65, F1 score of 0.70, AUROC of 0.74 and AUCPR of 0.75). In a retrospective evaluation simulating real-life use, the voting classifier model successfully identified 45% of the total patients selected who were found to have at least one unintended discrepancy compared to 21% when using the existing tool. The positive experimental results of this tool showed a superior improvement of 113% over the existing tool by targeting patients at risk of medication errors upon admission to Reims University Hospital.


  • Characteristics of hospital pharmacist interventions and their clinical, economic and organizational impacts: a five-year observational study on the French National Observatory

    by Justine Clarenne, Céline Mongaret, Céline Vermorel, Jean Luc Bosson, Sophie C. Gangloff, Sophie Lambert-Lacroix, Pierrick Bedouch

    Background Since 2006, French hospital pharmacists have been able to document their interventions in the National Observatory Act-IP© and, since 2016, to assess the potential clinical, economic and organizational impacts of pharmacist interventions (PIs) via the CLEO© tool. Aim To describe pharmacist interventions in French hospitals from 2017 to 2021 and to evaluate their potential impacts using the CLEO© tool. Method The study was conducted to examine PIs documented in the Act-IP© Observatory. For each intervention, the pharmacist used the CLEO© tool to evaluate the clinical impact, using a six-point scale ranging from negative to avoiding a fatality; the economic impact, i.e., whether there was a decrease or an increase in direct costs; and whether there was a positive or negative organizational impact from the health care providers’ perspective. Results 121,792 PIs were assessed using the CLEO© tool for at least one outcome. Interventions with a potentially significant clinical impact accounted for 84.3% interventions and were classified as follows: minor, 28.3%; moderate, 40.3%; major, 15.0%; and avoiding a fatality, 0.7%, impacts. These interventions mainly involved antineoplastics, antithrombotic agents and some antibacterial agents. Most of the pharmacist interventions led to decreases in direct costs (50.4%) and positive organizational impacts (61.0%), especially for proton pomp inhibitors. Conclusion Many PIs have positive clinical, economic and organizational impacts, which highlights the added value of pharmacists in patient safety and positive impacts on health care teams. The pertinence of PIs can now be assessed by the CLEO© tool with a broader focus than prescribers’ acceptance.


  • 15e remise du prix inter-facultés de dispensation d’ordonnance : retour sur une journée riche en éloquence

    by Cécile Detuncq, Elodie Matusik, Justine Clarenne, Elsa Jouhanneau, Sara Belhadj

  • Open Access

    Intégrer les systèmes d’aide à la décision pharmaceutique dans les pratiques de pharmacie clinique. Pourquoi ? Comment ?

    by Arnaud Potier, Chloé Rousselière, Hélène Eychenié, Justine Clarenne, Rémy Collomp


  • Open Access

    Clinical and Organizational Impacts of Medical Ordering Settings on Patient Pathway and Community Pharmacy Dispensing Process: The Prospective ORDHOSPIVILLE Study

    by Justine Clarenne, Julien Gravoulet, Virginie Chopard, Julia Rouge, Amélie Lestrille, François Dupuis, Léa Aubert, Sophie Malblanc, Coralie Barbe, Florian Slimano, et al.

    During the dispensing process of medical orders (MOs), community pharmacists (CPs) can manage drug-related problems (DRPs) by performing pharmacist interventions (PIs). There is little evidence that the PI rate is higher with MOs from hospitals (MOHs) than ambulatory (MOAs) settings, and their impact on the patient and community pharmacy is unknown. The primary objective of this study was to compare the MOH and MOA PI rates. The secondary objective was to describe PIs and their clinical and organizational impacts on patient and community pharmacy workflow. A total of 120 CPs participated in a prospective study. Each CP included 10 MOH and 10 MOA between January and June 2020. DRP and PI description and clinical and organizational impacts between MOH and MOA were assessed and compared. We analyzed 2325 MOs. PIs were significantly more frequent in MOH than in MOA (9.7% versus 4.7%; p < 0.001). The most reported PI was the difficulty of contacting hospital prescribers (n = 45; 52.2%). MOHs were associated with a longer dispensing process time and a greater impact on patient pathway and community pharmacy workflow than MOAs. Lack of communication between hospital and primary care settings partly explains the results. Implementation of clinical pharmacy activities at patient discharge could alleviate these impacts.


  • Open Access

    Clinical Relevance of Pharmacist Intervention: Development of a Named Entity Recognition Model on Unstructured Comments

    by Justine Clarenne, Sonia Priou, Aymeric Alixe, Olivier Martin, Céline Mongaret, Pierrick Bedouch

    We developed a clinical named entity recognition model to predict clinical relevance of pharmacist interventions (PIs) by identifying and labelling expressions from unstructured comments of PIs. Three labels, drug, kidney and dosage, had a great inter-annotator agreement (>60%) and could be used as reference labelization. These labels also showed a high precision (>70%) and a variable recall (50-90 %).